Skip to main content

Advertisement

SpringerLink
Log in

Treatment of patients comorbid for addiction and other psychiatric disorders

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Psychiatric disorders and drug and alcohol use disorders commonly co-occur. A growing literature has documented the epidemiology and effects on the course of illness of comorbid psychiatric and substance use disorders (SUDs). Advances in treatment of co-occuring illnesses have progressed more slowly. The current article reviews recent developments in the diagnosis and treatment of co-occurring psychiatric disorders and SUDs with particular focus on psychotic disorders, affective disorders, anxiety disorders, personality disorders, and attention-deficit/hyperactivity disorder. Current treatment options and implications for future research are highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Regier DA, Farmer ME, Rae DS, et al.: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511–2518.

    Article  PubMed  CAS  Google Scholar 

  2. Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8–19.

    PubMed  CAS  Google Scholar 

  3. Conway KP, Compton W, Stinson FS, Grant BF: Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006, 67:247–257.

    Article  PubMed  CAS  Google Scholar 

  4. Kessler RC, Birnbaum H, Demler O, et al.: The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry 2005, 58:668–676.

    Article  PubMed  Google Scholar 

  5. Kessler RC, Chiu WT, Demler O, et al.: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617–627.

    Article  PubMed  Google Scholar 

  6. Swartz MS, Wagner HR, Swanson JW, et al.: Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006, 194:164–172.

    Article  PubMed  Google Scholar 

  7. Green AI: Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. J Clin Psychiatry 2006, 67(Suppl 7):31–35. Quiz 36–37.

    PubMed  Google Scholar 

  8. Stuyt EB, Sajbel TA, Allen MH: Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 2006, 15:166–173.

    Article  PubMed  Google Scholar 

  9. Petrakis IL, Leslie D, Finney JW, Rosenheck R: Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 2006, 15:44–49.

    Article  PubMed  Google Scholar 

  10. Brunette MF, Drake RE, Xie H, et al.: Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006, 32:637–643.

    Article  PubMed  Google Scholar 

  11. Farren CK, Hameedi FA, Rosen MA, et al.: Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend 2000, 59:153–163.

    Article  PubMed  CAS  Google Scholar 

  12. Smelson DA, Tunis SL, Nyhuis AW, et al.: Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacol 2006, 26:666–667.

    Article  PubMed  Google Scholar 

  13. Sayers SL, Campbell EC, Kondrich J, et al.: Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005, 193:379–386.

    Article  PubMed  Google Scholar 

  14. Linszen D, van Amelsvoort T: Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry 2007, 20:116–120.

    Article  PubMed  Google Scholar 

  15. Potvin S, Stip E, Lipp O, et al.: Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006, 22:1277–1285.

    Article  PubMed  CAS  Google Scholar 

  16. Pierre JM, Shnayder I, Wirshing DA, Wirshing WC: Intranasal quetiapine abuse. Am J Psychiatry 2004, 161:1718.

    Article  PubMed  Google Scholar 

  17. Beresford TP, Clapp L, Martin B, et al.: Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005, 25:363–366.

    Article  PubMed  CAS  Google Scholar 

  18. Brown ES, Jeffress J, Liggin JD, et al.: Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005, 66:756–760.

    PubMed  Google Scholar 

  19. Rubio G, Martinez I, Ponce G, et al.: Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006, 51:531–539.

    PubMed  Google Scholar 

  20. Huguelet P, Morand-Collomb S: Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res 2005, 52:392–394.

    Article  PubMed  CAS  Google Scholar 

  21. Petrakis IL, Nich C, Ralevski E: Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 2006, 32:644–654.

    Article  PubMed  Google Scholar 

  22. Petrakis IL, O’Malley S, Rounsaville B, et al.: Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004, 172:291–297.

    Article  CAS  Google Scholar 

  23. Bellack AS, Bennett ME, Gearson JS, et al.: A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006, 63:426–432.

    Article  PubMed  Google Scholar 

  24. Ries RK, Short RA, Dyck DG, Srebnik DS: Unlinking disability income, substance use and adverse outcomes in dually diagnosed, severely mentally ill outpatients. Am J Addict 2004, 13:390–397.

    Article  PubMed  Google Scholar 

  25. Rosen MI, McMahon TJ, Rosenheck R: Does assigning a representative payee reduce substance abuse? Drug Alcohol Depend 2007, 86:115–122.

    Article  PubMed  Google Scholar 

  26. Grant BF, Stinson FS, Dawson DA, et al.: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004, 61:807–816.

    Article  PubMed  Google Scholar 

  27. Weiss RD, Ostacher MJ, Otto MW, et al.: Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry 2005, 66:730–735. Quiz 808–809.

    Article  PubMed  Google Scholar 

  28. Strakowski SM, DelBello MP, Fleck DE, et al.: Effects of co-occurring alcohol abuse on the course of bipolar disorder following a first hospitalization for mania. Arch Gen Psychiatry 2005, 62:851–858.

    Article  PubMed  Google Scholar 

  29. Fossey MD, Otto MW, Yates WR, et al.: Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants. Am J Addict 2006, 15:138–143.

    Article  PubMed  Google Scholar 

  30. Salloum IM, Cornelius JR, Daley DC, et al.: Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005, 62:37–45.

    Article  PubMed  CAS  Google Scholar 

  31. Brown ES, Perantie DC, Dhanani N, et al.: Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disord 2006, 93:219–222.

    Article  PubMed  CAS  Google Scholar 

  32. Rubio G, Lopez-Munoz F, Alamo C: Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 2006, 8:289–293.

    Article  PubMed  CAS  Google Scholar 

  33. Verduin ML, McRae AL, Tolliver BK, et al.: Efficacy of aripiprazole in patients with substance use disorders. Paper presented at the 69th Annual Meeting of the College on Problems of Drug Dependence. Quebec City, Quebec; June 12–17, 2007.

  34. Tolliver BK, McRae AL, Verduin ML, et al.: A comparison of the efficacy of aripiprazole on psychiatric and substance use outcomes in bipolar and schizophrenic patients. Paper presented at the 69th Annual Meeting of the College on Problems of Drug Dependence. Quebec City, Quebec; June 12–17, 2007.

  35. Brown ES, Beard L, Dobbs L, Rush AJ: Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety 2006, 23:492–495.

    Article  PubMed  CAS  Google Scholar 

  36. Weiss RD, Griffin ML, Kolodziej ME, et al.: A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 2007, 164:100–107.

    Article  PubMed  Google Scholar 

  37. Hasin DS, Goodwin RD, Stinson FS, Grant BF: Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005, 62:1097–1106.

    Article  PubMed  Google Scholar 

  38. Gilman SE, Abraham HD: A longitudinal study of the order of onset of alcohol dependence and major depression. Drug Alcohol Depend 2001, 63:277–286.

    Article  PubMed  CAS  Google Scholar 

  39. Nunes EV, Levin FR: Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004, 291:1887–1896.

    Article  PubMed  CAS  Google Scholar 

  40. Carpenter KM, Brooks AC, Vosburg SK, Nunes EV: The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend 2004, 74:123–134.

    Article  PubMed  CAS  Google Scholar 

  41. Hien DA, Cohen LR, Miele GM, et al.: Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry 2004, 161:1426–1432.

    Article  PubMed  Google Scholar 

  42. Petrakis IL, Poling J, Levinson C, et al.: Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry 2006, 60:777–783.

    Article  PubMed  CAS  Google Scholar 

  43. Brady KT, Wilens TE, Adler LA, et al.: Atomoxetine treatment of adults with ADHD and comorbid alcohol abuse disorder. Paper presented at the Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, FL; December 10–15, 2006.

  44. Grant BF, Stinson FS, Dawson DA, et al.: Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004, 61:361–368.

    Article  PubMed  Google Scholar 

  45. Lenzenweger MF, Lane MC, Loranger AW, Kessler RC: DSM-IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007 [Epub ahead of print].

  46. Compton WM, 3rd, Cottler LB, Jacobs JL, et al.: The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry 2003, 160:890–895.

    Article  PubMed  Google Scholar 

  47. Haro G, Mateu C, Martinez-Raga J, et al.: The role of personality disorders on drug dependence treatment outcomes following inpatient detoxification. Eur Psychiatry 2004, 19:187–192.

    Article  PubMed  CAS  Google Scholar 

  48. Darke S, Williamson A, Ross J, et al.: Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 2004, 74:77–83.

    Article  PubMed  Google Scholar 

  49. Messina N, Farabee D, Rawson R: Treatment responsivity of cocaine-dependent patients with antisocial personality disorder to cognitive-behavioral and contingency management interventions. J Consult Clin Psychol 2003, 71:320–329.

    Article  PubMed  Google Scholar 

  50. O’Brien CP, Charney DS, Lewis L, et al.: Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry 2004, 56:703–713.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 67 President Street, Charleston, SC, 29425, USA

    Kathleen T. Brady

Authors
  1. Kathleen T. Brady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcia L. Verduin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bryan K. Tolliver
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen T. Brady.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brady, K.T., Verduin, M.L. & Tolliver, B.K. Treatment of patients comorbid for addiction and other psychiatric disorders. Curr Psychiatry Rep 9, 374–380 (2007). https://doi.org/10.1007/s11920-007-0048-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-007-0048-0

Keywords

Search

Navigation